Targeting a specific protein to prevent pancreatic cancer progression
Neutralizing Stromal NetrinG1 to Intercept Pancreatic Cancer
This study is looking at a new way to stop pancreatic cancer from developing by targeting a protein called Netrin G1, and it's especially for people who have a family history of pancreatic cancer or certain risk factors.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10909965 on NIH RePORTER |
What this research studies
This research investigates a novel approach to intercept pancreatic cancer by targeting a protein called Netrin G1, which is involved in the growth of precancerous tissues. The study aims to identify and screen agents that can disrupt the signaling pathways of this protein, potentially preventing the progression of early-stage pancreatic cancer. By focusing on the unique microenvironment of pancreatic tumors, the research seeks to develop strategies for early detection and intervention, particularly for high-risk patients. Patients with a family history of pancreatic cancer or those with certain predisposing conditions may find this research particularly relevant.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with hereditary pancreatic cancer risk factors, such as family history or specific genetic mutations, as well as those with conditions like pancreatitis or new-onset diabetes.
Not a fit: Patients with advanced pancreatic cancer or those without any known risk factors for the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new prevention strategies that significantly improve outcomes for patients at high risk of developing pancreatic cancer.
How similar studies have performed: This approach is novel and has not been extensively tested in previous research, making it a potentially groundbreaking strategy in pancreatic cancer prevention.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Cukierman, Edna — Research Inst of Fox Chase Can Ctr
- Study coordinator: Cukierman, Edna
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.